Molecular Pathology of Lung and Thoracic Cancers

Message from the Guest Editor

Dear Colleagues,

Lung cancer is the most common type of thoracic cancer, making the most lethal cancer worldwide. Despite improvements in early detection, surgical treatment, systemic therapy, and radiotherapy, most patients with thoracic cancer are diagnosed at an advanced stage and have a poor prognosis.

The scope of this Special Issue is to attract original research as well as review articles describing all aspects of tissue- or biofluid-based molecular biomarkers of lung cancer and other types of thoracic cancer, including thymic tumors and mesothelioma. Potential topics include but are not limited to the following: discovery and/or validation of diagnostic, prognostic, and therapeutic molecular biomarkers; method development for data acquisition and analysis; statistical and bioinformatic approaches to biomarker discovery and development of omics-based signatures; and integration and development of biomarker model.

Dr. Ayumu Taguchi
Guest Editor

Deadline for manuscript submissions: 31 August 2019